According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevale...According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevalent cancer,following only after lung cancer(2).The first version of the Chinese Society of Clinical Oncology(CSCO)guideline was launched in 2017 and has been updated annually based on the latest findings of clinical research,drug accessibility and expert consensus(3-8).Here,we present the main updates of the 2024 version compared to the 2023 version.展开更多
Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society o...Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guideline was published in2017,the guideline has been updated annually according to the latest results of clinical research at home and abroad,the accessibility of drugs and the opinions of CSCO experts(3-7).展开更多
Colorectal cancer(CRC)is the second most common cancer in China,the morbidity and mortality rates of which are rapidly increasing1,2.Among newly-diagnosed CRC patients,20%have metastatic disease at the time of present...Colorectal cancer(CRC)is the second most common cancer in China,the morbidity and mortality rates of which are rapidly increasing1,2.Among newly-diagnosed CRC patients,20%have metastatic disease at the time of presentation and an additional 25%present with localized disease and will subsequently develop metastases3.The treatment of metastatic colorectal cancer(mCRC)is gradually moving towards the era of precision therapy,which involves guided treatment based on individual genetic characteristics4.Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guidelines was published in 2017,the guidelines have been updated annually according to the latest clinical trial findings5-9.Herein we summarize how the CSCO guidelines enable tailor-made treatments of mCRC with different molecular characteristics(Figure 1).展开更多
Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,...Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,100 deaths of CRC in China, accounting for 9.87% and 8.01% of all malignancies. The first version of the Chinese Society of Clinical Oncology(CSCO) guidelines was released in April2017, and has been updated annually based on the latest clinical research data and the availability of new drugs(2-4). Here, we present the main updates of the 2021 version compared to 2020 version.展开更多
Colorectal cancer(CRC) is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020(1). Recent data show that the incidence and mortality of CRC in C...Colorectal cancer(CRC) is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020(1). Recent data show that the incidence and mortality of CRC in China are increasing(2-4), with the number of new cases and deaths reaching 607,900 and 261,777 in 2019.展开更多
According to the latest data released by the National Cancer Center,colorectal cancer(CRC)had the third highest incidence and the fifth highest mortality of all malignancies,with 388,000 new cases and 187,000 cancer d...According to the latest data released by the National Cancer Center,colorectal cancer(CRC)had the third highest incidence and the fifth highest mortality of all malignancies,with 388,000 new cases and 187,000 cancer deaths in China(1).The Chinese Society of Clinical Oncology(CSCO)originally published the English version of 2018 guideline concerning CRC and updated them in2019(2,3).According to the latest progress,clinical guidelines have been updated.Here,we present the main updates of the 2020 version compared to 2019 version.展开更多
In this White Paper we present the potential of the enhanced X-ray Timing and Polarimetry(eXTP) mission for studies related to Observatory Science targets. These include flaring stars, supernova remnants, accreting wh...In this White Paper we present the potential of the enhanced X-ray Timing and Polarimetry(eXTP) mission for studies related to Observatory Science targets. These include flaring stars, supernova remnants, accreting white dwarfs, low and high mass X-ray binaries, radio quiet and radio loud active galactic nuclei, tidal disruption events, and gamma-ray bursts. eXTP will be excellently suited to study one common aspect of these objects: their often transient nature. Developed by an international Consortium led by the Institute of High Energy Physics of the Chinese Academy of Science, the eXTP mission is expected to be launched in the mid 2020s.展开更多
基金supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)National Natural Science Foundation of China(No.82373415 and No.82302489)Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003).
文摘According to the latest global cancer statistics,colorectal cancer(CRC)is the most common malignancy of the digestive system and the second most lethal among all cancer types(1).In China,CRC is the second most prevalent cancer,following only after lung cancer(2).The first version of the Chinese Society of Clinical Oncology(CSCO)guideline was launched in 2017 and has been updated annually based on the latest findings of clinical research,drug accessibility and expert consensus(3-8).Here,we present the main updates of the 2024 version compared to the 2023 version.
基金supported by the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)Beijing Xisike Clinical Oncology Research Foundation(No.Y-tongshu2021/ms-0003)。
文摘Colorectal cancer(CRC)is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China(1,2).Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guideline was published in2017,the guideline has been updated annually according to the latest results of clinical research at home and abroad,the accessibility of drugs and the opinions of CSCO experts(3-7).
基金supported by the Provincial Key R&D Program of Zhejiang Province(Grant No.2021C03125)the Beijing Xisike Clinical Oncology Research Foundation(Grant No.Y-tongshu2021/ms-0003).
文摘Colorectal cancer(CRC)is the second most common cancer in China,the morbidity and mortality rates of which are rapidly increasing1,2.Among newly-diagnosed CRC patients,20%have metastatic disease at the time of presentation and an additional 25%present with localized disease and will subsequently develop metastases3.The treatment of metastatic colorectal cancer(mCRC)is gradually moving towards the era of precision therapy,which involves guided treatment based on individual genetic characteristics4.Since the first edition of the Chinese Society of Clinical Oncology(CSCO)guidelines was published in 2017,the guidelines have been updated annually according to the latest clinical trial findings5-9.Herein we summarize how the CSCO guidelines enable tailor-made treatments of mCRC with different molecular characteristics(Figure 1).
基金supported by the National Key R&D Program of China (No. 2018YFC1312100)the National Natural Science Foundation of China (No. 81872481)Traditional Chinese Medicine (Integrated Chinese and Western Medicine) Key Discipline Construction Project of Zhejiang Province (No. 2017-XK-A40)。
文摘Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,100 deaths of CRC in China, accounting for 9.87% and 8.01% of all malignancies. The first version of the Chinese Society of Clinical Oncology(CSCO) guidelines was released in April2017, and has been updated annually based on the latest clinical research data and the availability of new drugs(2-4). Here, we present the main updates of the 2021 version compared to 2020 version.
基金supported by the National Natural Science Foundation of China(No.81872481)the Provincial Key R&D Program of Zhejiang Province(No.2021C03125)。
文摘Colorectal cancer(CRC) is the third most common cancer worldwide and the second most common in tumor-related mortality by Global Cancer Statistics 2020(1). Recent data show that the incidence and mortality of CRC in China are increasing(2-4), with the number of new cases and deaths reaching 607,900 and 261,777 in 2019.
文摘According to the latest data released by the National Cancer Center,colorectal cancer(CRC)had the third highest incidence and the fifth highest mortality of all malignancies,with 388,000 new cases and 187,000 cancer deaths in China(1).The Chinese Society of Clinical Oncology(CSCO)originally published the English version of 2018 guideline concerning CRC and updated them in2019(2,3).According to the latest progress,clinical guidelines have been updated.Here,we present the main updates of the 2020 version compared to 2019 version.
基金supported by the Royal Society,ERC Starting(Grant No.639217)he European Union Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Global Fellowship(Grant No.703916)+10 种基金the National Natural Science Foundation of China(Grant Nos.11233001,11773014,11633007,11403074,11333005,11503008,and 11590781)the National Basic Research Program of China(Grant No.2015CB857100)NASA(Grant No.NNX13AD28A)an ARC Future Fellowship(Grant No.FT120100363)the National Science Foundation(Grant No.PHY-1430152)the Spanish MINECO(Grant No.AYA2016-76012-C3-1-P)the ICCUB(Unidad de Excelencia’Maria de Maeztu’)(Grant No.MDM-2014-0369)EU’s Horizon Programme through a Marie Sklodowska-Curie Fellowship(Grant No.702638)the Polish National Science Center(Grant Nos.2015/17/B/ST9/03422,2015/18/M/ST9/00541,2013/10/M/ST9/00729,and 2015/18/A/ST9/00746)the Strategic Priority Research Program of the Chinese Academy of Sciences(Grant No.XDA15020100)the NWO Veni Fellowship(Grant No.639.041.647)
文摘In this White Paper we present the potential of the enhanced X-ray Timing and Polarimetry(eXTP) mission for studies related to Observatory Science targets. These include flaring stars, supernova remnants, accreting white dwarfs, low and high mass X-ray binaries, radio quiet and radio loud active galactic nuclei, tidal disruption events, and gamma-ray bursts. eXTP will be excellently suited to study one common aspect of these objects: their often transient nature. Developed by an international Consortium led by the Institute of High Energy Physics of the Chinese Academy of Science, the eXTP mission is expected to be launched in the mid 2020s.
